Public Health Key Documents: August 2023

NIHR

Nil

The King's Fund

Nil

Scottish Government

Independent Review of Audiology Services in Scotland

There are multiple, systemic problems within audiology services in NHS Scotland. There has been a lack of profile, national oversight, accountability and clarity around Health Board-level clinical governance arrangements. There has also been an absence of national leadership, strategic planning and workforce planning. In recent years there has been no quality assurance of services, despite the existence of national quality standards for paediatric and adult audiology services. There is clear evidence of workforce shortages, limited access to training programmes and few opportunities for continuing professional development and skills maintenance and acquisition once in post. Resolving these failings requires a whole-system approach. The recommendations in this report seek to provide the foundation for improvements that will ensure high-quality, joined-up, patient-centred services.

Systematic search: No

August 2023

https://www.gov.scot/publications/independent-review-audiology-services-scotland/

Managed Clinical Networks: report

Independent report on Managed Clinical Networks, with specific focus on the Hearing Impairment Network for Children and Young People.

Systematic search: No

August 2023

https://www.gov.scot/publications/managed-clinical-networks-report/

Infant food insecurity: summary report

Report from an event held in June 2023 on infant food insecurity in Scotland, by the Scottish Government and partner organisations to inform next steps and key learning to shape local emergency pathways. The event included a presentation by Denise Forsyth, Welfare Team Leader, Aberdeenshire Council.

Systematic search: No

August 2023

https://www.gov.scot/publications/infant-food-insecurity-summary-report/

SIGN

Nil

Public Health Scotland

Community anchor case study: Widening participation education programme, NHS Grampian

This case study demonstrates NHS Grampian working with various partners, such as schools, universities and the local council, to encourage young people from deprived backgrounds to think about careers in healthcare, while thinking about their own health. As an anchor, the board demonstrates its role in making a positive impact for the next generation of young people going into employment in healthcare.

Systematic search: No

August 2023

https://www.publichealthscotland.scot/publications/community-anchor-case-study-widening-participation-education-programme-nhs-grampian

Community anchor case study: Diversifying NHS Greater Glasgow and Clyde's supply chain

NHS Greater Glasgow and Clyde worked in partnership with six health and social care partnerships to diversify the NHS Board's supply chain with the aim of supporting more local diverse small businesses that are run by, and for, specific population groups. As an anchor, the board demonstrates its role in improving procurement processes to help bring wealth back into local and diverse communities.

Systematic search: No

August 2023

https://www.publichealthscotland.scot/publications/community-anchor-case-study-diversifying-nhs-greater-glasgow-and-clyde-s-supply-chain/

Community anchor case study: NHS Ayrshire & Arran approach to community wealth building

This case study reflects on the approach NHS Ayrshire and Arran has taken to move the agenda of community wealth building forward. It examines how they got "buy-in" from senior leaders, and how they aim to increase knowledge on community wealth building with staff at all levels. Systematic search: No

August 2023

https://www.publichealthscotland.scot/publications/community-anchor-case-study-nhs-ayrshire-arran-approach-to-community-wealth-building

Scottish Medicines Consortium (SMC Advice)

dapagliflozin (Forxiga®)

Accepted for use within NHSScotland in adults for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction (LVEF) >40%.

Systematic search: No

August 2023

https://www.scottishmedicines.org.uk/medicines-advice/dapagliflozin-forxiga-abb-smc2577/

icosapent ethyl (Vazkepa®)

Accepted, subject to a number of restrictions, for use to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (≥1.7mmol/L) and established cardiovascular disease, or diabetes, and at least one other cardiovascular risk factor. Systematic search: No

August 2023

https://www.scottishmedicines.org.uk/medicines-advice/icosapent-ethyl-vazkepa-ft-resub-smc2602/

tezepelumab (Tezspire®)

Accepted for restricted use as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Systematic search: No

August 2023

https://www.scottishmedicines.org.uk/medicines-advice/tezepelumab-tezspire-full-smc2541/

baricitinib (Olumiant®)

NOT recommended for use for the treatment of severe alopecia areata in adult patients.

Systematic search: No

August 2023

https://www.scottishmedicines.org.uk/medicines-advice/baricitinib-olumiant-full-smc2572/

selumetinib (Koselugo®)

NOT recommended for use as monotherapy for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and above.

Systematic search: No

August 2023

https://www.scottishmedicines.org.uk/medicines-advice/selumetinib-koselugo-full-smc2540/

NICE - Technology Appraisal Guidance

TA912 Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease

Cipaglucosidase alfa (CIPA) plus miglustat is recommended as an option for treating late-onset Pompe disease in adults.

Systematic search: Limited

August 2023

https://www.nice.org.uk/guidance/ta912

NICE - Guidelines

NG12 Suspected cancer: recognition and referral (Updated)

Covers identifying children, young people and adults with symptoms that could be caused by cancer. The recommendations on colorectal cancer have been partially updated in line with NICE's diagnostic guidance on quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care.

Systematic search: Limited

August 2023

https://www.nice.org.uk/guidance/ng12

UKHSA Knowledge & Library Services evidence briefings & syntheses

What is the evidence that shows location can act as a driver for collaboration with external partners?

A literature search found evidence that: close geographic proximity of partners is not necessarily a success factor for innovation; geographic proximity can facilitate knowledge spillovers through the exchange of tacit information; partnerships between academia and local communities can significantly improve the quality of life for members of their communities; being aware of the qualities of each stakeholder can improve outcomes; universities working with local communities have the potential to accelerate creativity; face-to-face meetings are vital for important decisions; strong networks can facilitate innovation and improve knowledge production as they reduce uncertainty and risk; trust among partners and stakeholders is essential; a Memorandum of Understanding can provide a framework for how the partnership will operate; cultural differences and expectations can bring fresh viewpoints to research outputs.

Systematic search: Limited

August 2023

https://ukhsa.koha-ptfs.co.uk/cgi-bin/koha/opac-retrieve-file.pl?id=3fa2d4717258d983779a789d81a5a99e

EPPI Centre

Nil

AHRQ (Agency for Healthcare Research and Quality – USA)

Nil

Health Foundation

Health in 2040: projected patterns of illness in England

9.1 million people in England are projected to be living with major illness by 2040, 2.5 million more than in 2019. This is an increase from almost 1 in 6 to nearly 1 in 5 of the adult population. Most of this rise is the result of an ageing population. Much of the projected growth in illness relates to conditions such as anxiety and depression, chronic pain and diabetes, which are predominantly managed in primary care and the community. This reinforces the need for investment in general practice and community-based services, focusing on prevention and early intervention. The number of people living with major illness is projected to increase by 37% – over a third – by 2040, nine times the rate at which the working age population (20–69-year-olds) is expected to grow (4%). Systematic search: No

July 2023

https://www.health.org.uk/publications/health-in-2040

Canadian Agency for drugs and Technologies in Health (CADTH)

Transcatheter Edge-ToEdge Valve Repair for Tricuspid Regurgitation

The transcatheter edge-to-edge valve repair (TEER) device (TriClip) might be more effective in reducing tricuspid regurgitation severity and improving quality of life compared to medical therapy alone. It may have little impact on all-cause mortality, hospitalization due to heart failure, and 6-minute walk tests compared to medical therapy alone. The TEER device (TriClip) demonstrated a numerically higher rate of adverse events than a medical therapy control group in a clinical trial. Systematic search: Yes

August 2023

https://www.cadth.ca/transcatheter-edge-edge-valve-repair-tricuspid-regurgitation

Lipid Panel Screening for Adults Living With Chronic Conditions

Abnormal blood lipid levels are associated with increased risk of cardiovascular disease, and lipid panel screening can help health care providers make treatment decisions for adults living with chronic conditions. No studies on the diagnostic test accuracy or clinical utility of nonfasting lipid panel screening for adults living with chronic conditions were found. Two guidelines recommend a nonfasting lipid panel for the initial screening for cardiovascular disease risk. A fasting lipid panel is recommended if triglyceride levels are high. One guideline recommends either fasting or nonfasting lipid panel screening before starting lipid modification therapy in people at risk of cardiovascular disease.

Systematic search: Yes

August 2023

https://www.cadth.ca/lipid-panel-screening-adults-living-chronic-conditions

At-Home Polysomnography Versus In-Clinic Polysomnography for Sleep Disorders

Evidence of low quality indicates that Level 2 PSG may have moderate accuracy compared to Level 1 PSG for diagnosing obstructive sleep apnea. There may be no significant differences in daytime sleepiness, hypertension, treatment adherence, and most quality-of-life measures for patients with OSA who were diagnosed with a Level 2 PSG compared with a Level 1 PSG (1 study).

Systematic search: Yes

August 2023

https://www.cadth.ca/home-polysomnography-versus-clinic-polysomnography-sleep-disorders

Emergency Care Follow-Up for Children and Adolescents with Suicide Attempts or Ideation

Active follow-up care following an emergency department visit for a suicide attempt is common; however, it is unclear what type (e.g., text message, home visit) or timing (e.g., 24 hours, within 72 hours after emergency department discharge) of interventions is most effective for preventing further self-harm in people younger than 18 years. For children and adolescents presenting to the emergency department for suicide attempts or ideation, telephone-based follow-up care initiated within 1 week of discharge may not affect the number of people who completed the full course of postdischarge treatment, the mean number of sessions attended, or the number of suicide deaths. This finding was based on evidence from 2 systematic reviews, each with 1 primary study relevant to this report. The small sample sizes of these studies and their limited or unclear quality should be considered when interpreting these results.

Systematic search: Yes

August 2023

https://www.cadth.ca/emergency-care-follow-children-and-adolescents-suicide-attempts-orideation

McGill University Health Centre (Canada)

Nil

Health Information & Quality Authority (Ireland) – Health Technology Assessments

Rapid health technology assessment of the extension of the seasonal influenza vaccination programme to include those aged 50 to 64 years (general population)

The rapid assessment noted uncertainty about the potential costs and benefits with extending the current vaccination programme and concluded the potential benefits for the HSE in extending the flu vaccination programme for the 2023-2024 season may be small.

Systematic search: Yes

August 2023

https://www.hiqa.ie/reports-and-publications/health-technology-assessment/rapid-health-technology-assessment-extension

Campbell Collaboration

Exploring Covid-19 education to support vaccine confidence amongst the general adult population with special considerations for healthcare and long-term care staff: A scoping review

Various educational interventions were delivered during the COVID-19 pandemic, with many initiatives involving multifaceted interventions utilizing both formal and informal approaches that leveraged community (cultural, religious) partnerships when developing and facilitating COVID-19 vaccine education. Train-the-trainer approaches with recognized community members could be of value as trust and personal connections were identified as strong enablers throughout the review. Systematic search: Limited

August 2023

https://www.campbellcollaboration.org/better-evidence/covid-19-education-scoping-review.html

Glasgow Centre for Population Health

Moving from homelessness into social housing: testing new approaches

Between 2019 and 2020, four Registered Social Landlords (RSL) in Glasgow worked with Glasgow City Council homelessness casework teams, homelessness outreach support services, the Scottish Welfare Fund (SWF), and a furniture provider to test new ways of supporting people moving from temporary homeless accommodation to a social housing tenancy. To prevent delays in taking up a new tenancy, the pilot aims were to fast-track Community Care Grant awards and delivery of furniture and white goods, alongside the four participating RSLs offering a two-week discretionary rent allowance. It was anticipated that these approaches could prevent the build-up of rent arrears, which tend to accumulate when moving to the new tenancy, and so support the longer-term aim of sustaining tenancies and preventing future homelessness. GCPH led on the evaluation to assess the pilot's impacts, using data from 137 participating tenants and interviews with staff and tenants. It concluded that the pilot helped tenants to move into secure housing with minimal delays and good access to the supports required to make their new houses feel like homes. This type of positive start can only help improve sustainment of tenancies.

Systematic search: No

August 2023

https://www.gcph.co.uk/assets/0000/9928/Moving from homelessness into social housing - testing new approaches.pdf

The impacts of the cost-of-living crisis on disabled people

Written in collaboration with Glasgow Disability Alliance, this report presents a rapid examination of the impacts of the cost-of-living crisis on disabled people. It includes the direct experiences of disabled people living in Glasgow and a scoping review of emergent evidence from across the UK. It demonstrates the consequences of policies that do not protect the most vulnerable from the potential harms of the cost-of-living crisis. Many disabled people simply cannot afford to live a healthy or fulfilling life, adversely impacting both mental and physical health and severely compromising condition management. Recommendations are made to mitigate these impacts and to address the historical health and social inequalities experienced by disabled people.

Systematic search: Limited

August 2023

https://www.gcph.co.uk/assets/0000/9844/Col Disabled people.pdf

NICE FORWARD PLANNING – Publications due September 2023

Cirrhosis in over 16s: assessment and management

Clinical Guideline - update (new clinical practice evidence)

Intrapartum care for healthy women and babies (update)

Clinical Guideline - update (new clinical practice evidence)

Pegunigalsidase alfa for treating Fabry disease

Technology Appraisal

Talazoparib for treating BRCA 1 or 2 mutated advanced breast cancer after prior chemotherapy Technology Appraisal

Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B Technology Appraisal

Ruxolitinib for treating polycythaemia vera (review of TA356)

Technology Appraisal

Zanubrutinib for treating chronic lymphocytic leukaemia

Technology Appraisal